View in EDS PDF Full Text

Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders.

Saved in:
Bibliographic Details
Title: Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders.
Alternate Title: Efectividad real de benralizumab en pacientes mexicanos con asma eosinofílica grave: respondedores y superrespondedores.
Authors: Ramírez, Ulises NoelGarcía1, Aguilar Hinojosa, Nadia Karina2, Reyes, Saraid Cerda3, Campos Gutiérrez, Rosa Isela3, Castillón Benavides, Nidia Karen4, Velasco Santos, Jorge Isaac5, Núñez Martínez, Francisco Javier6, Flores, Homero Garcés7, Arballo Rivera, Gustavo Adolfo8, Flores Razo, Miriam Monzerrat9, Lizarazo Guiza, Paula Catalina10 catalina.lizarazo@astrazeneca.com
Source: Revista Alergia de Mexico. ene-mar2026, Vol. 73 Issue 1, p17-25. 9p.
Subjects: TREATMENT effectiveness, ANTIASTHMATIC agents, MEXICANS, ASTHMA, QUALITY of life
Geographic Terms: MEXICO
Abstract (English): OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico. METHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months. RESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed. CONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): OBJETIVO: Evaluar el tipo e intensidad de respuesta a benralizumab, e identificar a los pacientes respondedores y superrespondedores con asma eosinofílica grave. MÉTODOS: Estudio multicéntrico llevado a cabo en tres hospitales de México. Se evaluaron pacientes a través del Cuestionario de Control del Asma, mini cuestionario sobre calidad de vida en asma; además de la determinación de eosinófilos en sangre periférica, fracción exhalada de óxido nítrico, volumen de expiración forzada en 1 segundo (VEF1), antes y después de recibir tratamiento con benralizumab, y cantidad de exacerbaciones en 12 meses. RESULTADOS: Se analizaron los expedientes de 28 pacientes con asma eosinofílica grave, mal controlada. A los 12 meses, un 82.1% de los casos se clasificó en control, donde 82% fueron respondedores y 64% superrespondedores. El 75% de los pacientes no tuvo exacerbaciones, 89% mejoraron el puntaje ACT y 79% descontinuaron el tratamiento con corticoesteroides. Un 82% mostró un VEF1 mayor de 500 mL. Los puntajes de ACT demostraron una reducción promedio de 1.35 puntos y se reportó una reducción estadísticamente significativa de eosinófilos en sangre. CONCLUSIÓN: Este es el primer estudio en México que evalúa al subgrupo de pacientes superrespondedores a benralizumab con mejoría clínica, de laboratorio y calidad de vida. La mayoría fueron respondedores y 64% superrespondedores a los 12 meses de tratamiento [ABSTRACT FROM AUTHOR]
Copyright of Revista Alergia de Mexico is the property of Coleg. Mexicano de Inmunologia Clinica y Alergia A.C.; Soc. Lat. de Alergia, Asma e Inmunologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 192855044
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Efectividad real de benralizumab en pacientes mexicanos con asma eosinofílica grave: respondedores y superrespondedores.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ramírez%2C+Ulises+NoelGarcía%22">Ramírez, Ulises NoelGarcía</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Aguilar+Hinojosa%2C+Nadia+Karina%22">Aguilar Hinojosa, Nadia Karina</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Reyes%2C+Saraid+Cerda%22">Reyes, Saraid Cerda</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Campos+Gutiérrez%2C+Rosa+Isela%22">Campos Gutiérrez, Rosa Isela</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Castillón+Benavides%2C+Nidia+Karen%22">Castillón Benavides, Nidia Karen</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Velasco+Santos%2C+Jorge+Isaac%22">Velasco Santos, Jorge Isaac</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Núñez+Martínez%2C+Francisco+Javier%22">Núñez Martínez, Francisco Javier</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Flores%2C+Homero+Garcés%22">Flores, Homero Garcés</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Arballo+Rivera%2C+Gustavo+Adolfo%22">Arballo Rivera, Gustavo Adolfo</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Flores+Razo%2C+Miriam+Monzerrat%22">Flores Razo, Miriam Monzerrat</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Lizarazo+Guiza%2C+Paula+Catalina%22">Lizarazo Guiza, Paula Catalina</searchLink><relatesTo>10</relatesTo><i> catalina.lizarazo@astrazeneca.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Alergia+de+Mexico%22">Revista Alergia de Mexico</searchLink>. ene-mar2026, Vol. 73 Issue 1, p17-25. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22ANTIASTHMATIC+agents%22">ANTIASTHMATIC agents</searchLink><br /><searchLink fieldCode="DE" term="%22MEXICANS%22">MEXICANS</searchLink><br /><searchLink fieldCode="DE" term="%22ASTHMA%22">ASTHMA</searchLink><br /><searchLink fieldCode="DE" term="%22QUALITY+of+life%22">QUALITY of life</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22MEXICO%22">MEXICO</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico. METHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months. RESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed. CONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: OBJETIVO: Evaluar el tipo e intensidad de respuesta a benralizumab, e identificar a los pacientes respondedores y superrespondedores con asma eosinofílica grave. MÉTODOS: Estudio multicéntrico llevado a cabo en tres hospitales de México. Se evaluaron pacientes a través del Cuestionario de Control del Asma, mini cuestionario sobre calidad de vida en asma; además de la determinación de eosinófilos en sangre periférica, fracción exhalada de óxido nítrico, volumen de expiración forzada en 1 segundo (VEF1), antes y después de recibir tratamiento con benralizumab, y cantidad de exacerbaciones en 12 meses. RESULTADOS: Se analizaron los expedientes de 28 pacientes con asma eosinofílica grave, mal controlada. A los 12 meses, un 82.1% de los casos se clasificó en control, donde 82% fueron respondedores y 64% superrespondedores. El 75% de los pacientes no tuvo exacerbaciones, 89% mejoraron el puntaje ACT y 79% descontinuaron el tratamiento con corticoesteroides. Un 82% mostró un VEF1 mayor de 500 mL. Los puntajes de ACT demostraron una reducción promedio de 1.35 puntos y se reportó una reducción estadísticamente significativa de eosinófilos en sangre. CONCLUSIÓN: Este es el primer estudio en México que evalúa al subgrupo de pacientes superrespondedores a benralizumab con mejoría clínica, de laboratorio y calidad de vida. La mayoría fueron respondedores y 64% superrespondedores a los 12 meses de tratamiento [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Alergia de Mexico is the property of Coleg. Mexicano de Inmunologia Clinica y Alergia A.C.; Soc. Lat. de Alergia, Asma e Inmunologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=192855044
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.29262/ram.v73i1.1562
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 17
    Subjects:
      – SubjectFull: TREATMENT effectiveness
        Type: general
      – SubjectFull: ANTIASTHMATIC agents
        Type: general
      – SubjectFull: MEXICANS
        Type: general
      – SubjectFull: ASTHMA
        Type: general
      – SubjectFull: QUALITY of life
        Type: general
      – SubjectFull: MEXICO
        Type: general
    Titles:
      – TitleFull: Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ramírez, Ulises NoelGarcía
      – PersonEntity:
          Name:
            NameFull: Aguilar Hinojosa, Nadia Karina
      – PersonEntity:
          Name:
            NameFull: Reyes, Saraid Cerda
      – PersonEntity:
          Name:
            NameFull: Campos Gutiérrez, Rosa Isela
      – PersonEntity:
          Name:
            NameFull: Castillón Benavides, Nidia Karen
      – PersonEntity:
          Name:
            NameFull: Velasco Santos, Jorge Isaac
      – PersonEntity:
          Name:
            NameFull: Núñez Martínez, Francisco Javier
      – PersonEntity:
          Name:
            NameFull: Flores, Homero Garcés
      – PersonEntity:
          Name:
            NameFull: Arballo Rivera, Gustavo Adolfo
      – PersonEntity:
          Name:
            NameFull: Flores Razo, Miriam Monzerrat
      – PersonEntity:
          Name:
            NameFull: Lizarazo Guiza, Paula Catalina
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: ene-mar2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 00025151
          Numbering:
            – Type: volume
              Value: 73
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Revista Alergia de Mexico
              Type: main
ResultId 1